Benjamin Schachner
YOU?
Author Swipe
View article: Social media use among cardiothoracic surgeons: The online landscape and comparisons between subgroups
Social media use among cardiothoracic surgeons: The online landscape and comparisons between subgroups Open
Virtually all (99.6%) of cardiothoracic surgeons use professional networking platforms; however, social media use remains relatively low overall at 42.6%. These findings provide foundational data on how cardiothoracic surgeons engage with …
View article: Total aortic arch debranching with antegrade Thoracic Endovascular Aortic Repair (TEVAR) in acute non-A non-B aortic dissection
Total aortic arch debranching with antegrade Thoracic Endovascular Aortic Repair (TEVAR) in acute non-A non-B aortic dissection Open
View article: Total Aortic Arch Debranching with Antegrade Thoracic Endovascular Aortic Repair (TEVAR) in Acute Aortic Arch Dissection
Total Aortic Arch Debranching with Antegrade Thoracic Endovascular Aortic Repair (TEVAR) in Acute Aortic Arch Dissection Open
BACKGROUND The surgical evaluation and management of aortic arch dissections, in the absence of ascending aortic involvement, remains a grey area. It is during these scenarios where thorough evaluation of patient/family history, clinical p…
View article: Infective Endocarditis After Aortic Valve Replacement with Aorto- Ventricular Discontinuity: A Major Surgical Challenge with Acceptable Midterm Results
Infective Endocarditis After Aortic Valve Replacement with Aorto- Ventricular Discontinuity: A Major Surgical Challenge with Acceptable Midterm Results Open
View article: Neoantigen-specific CD4<sup>+</sup> tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients
Neoantigen-specific CD4<sup>+</sup> tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients Open
Background Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs) is a promising immunotherapeutic approach for patients with advanced solid tumors. While numerous advances have been made, the contribution of neoantigen-spe…
View article: Gynecologic oncology fellowship leadership trends by gender
Gynecologic oncology fellowship leadership trends by gender Open
Our objective was to examine the educational, research, and leadership trends among gynecologic oncology (GYO) fellowship program directors (PD) and how these vary by gender. PDs were identified using the Society of Gynecologic Oncology Fe…
View article: Cross-sectional Evaluation of Neurotology Fellowship Directors: A Present-day Snapshot of Leadership
Cross-sectional Evaluation of Neurotology Fellowship Directors: A Present-day Snapshot of Leadership Open
Objective: To identify demographic, training, and career trends of neurotology fellowship directors (FDs). Study Design: Cross-sectional study. Setting: United States. Subjects: All 26 neurotology FDs identified using the American Neurotol…
View article: Supplementary Figure 1 from Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma
Supplementary Figure 1 from Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma Open
Supplementary Figure 1 shows that central memory T cells were increase in the CD8+ TIL compartment of responders.
View article: Data from Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma
Data from Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma Open
Purpose:Metastatic melanoma is a tumor amenable to immunotherapy in part due to the presence of antigen-specific tumor-infiltrating lymphocytes (TIL). These T cells can be activated and expanded for adoptive cell transfer (ACT), which has …
View article: Supplementary Methods Table 1 from Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma
Supplementary Methods Table 1 from Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma Open
The Supplementary Methods Table contains the antibodies and panels in support of the Flow Cytometry section of the Materials and Methods.
View article: Supplementary Data not shown 1 from Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma
Supplementary Data not shown 1 from Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma Open
Data not shown in reference to related statements in manuscript.
View article: Supplementary Figure 1 from Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma
Supplementary Figure 1 from Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma Open
Supplementary Figure 1 shows that central memory T cells were increase in the CD8+ TIL compartment of responders.
View article: Supplementary Table 2 from Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma
Supplementary Table 2 from Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma Open
Supplementary Table 2 contains the Representativeness Table which demonstrates how this study fits into the larger patient population for metastatic melanoma.
View article: Supplementary Table 1 from Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma
Supplementary Table 1 from Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma Open
Supplementary Table 1 shows the distribution of Grade 3 and 4 non-hematologic adverse events reported in this study.
View article: Data from Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma
Data from Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma Open
Purpose:Metastatic melanoma is a tumor amenable to immunotherapy in part due to the presence of antigen-specific tumor-infiltrating lymphocytes (TIL). These T cells can be activated and expanded for adoptive cell transfer (ACT), which has …
View article: Supplementary Data not shown 1 from Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma
Supplementary Data not shown 1 from Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma Open
Data not shown in reference to related statements in manuscript.
View article: Supplementary Table 2 from Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma
Supplementary Table 2 from Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma Open
Supplementary Table 2 contains the Representativeness Table which demonstrates how this study fits into the larger patient population for metastatic melanoma.
View article: Supplementary Table 1 from Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma
Supplementary Table 1 from Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma Open
Supplementary Table 1 shows the distribution of Grade 3 and 4 non-hematologic adverse events reported in this study.
View article: Supplementary Methods Table 1 from Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma
Supplementary Methods Table 1 from Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma Open
The Supplementary Methods Table contains the antibodies and panels in support of the Flow Cytometry section of the Materials and Methods.
View article: The Impact of Targetable Mutations on Clinical Outcomes of Metastatic Epidural Spinal Cord Compression in Patients With Non–Small-Cell Lung Cancer Treated With Hybrid Therapy (Surgery Followed by Stereotactic Body Radiation Therapy)
The Impact of Targetable Mutations on Clinical Outcomes of Metastatic Epidural Spinal Cord Compression in Patients With Non–Small-Cell Lung Cancer Treated With Hybrid Therapy (Surgery Followed by Stereotactic Body Radiation Therapy) Open
BACKGROUND: In treatment of metastatic epidural spinal cord compression (MESCC), hybrid therapy, consisting of separation surgery, followed by stereotactic body radiation therapy, has become the mainstay of treatment for radioresistant pat…
View article: Long-Term Clinical Outcomes of Patients with Colorectal Cancer with Metastatic Epidural Spinal Cord Compression Treated with Hybrid Therapy (Surgery Followed by Stereotactic Body Radiation Therapy)
Long-Term Clinical Outcomes of Patients with Colorectal Cancer with Metastatic Epidural Spinal Cord Compression Treated with Hybrid Therapy (Surgery Followed by Stereotactic Body Radiation Therapy) Open
View article: Trends in leadership at breast surgical oncology fellowships
Trends in leadership at breast surgical oncology fellowships Open
View article: Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma
Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma Open
Purpose: Metastatic melanoma is a tumor amenable to immunotherapy in part due to the presence of antigen-specific tumor-infiltrating lymphocytes (TIL). These T cells can be activated and expanded for adoptive cell transfer (ACT), which has…
View article: Demographics and Academic Productivity of Cardiothoracic Imaging Fellowship Program Directors in the United States: A Cross-Sectional Review
Demographics and Academic Productivity of Cardiothoracic Imaging Fellowship Program Directors in the United States: A Cross-Sectional Review Open
Background In this study, we aimed to assess current demographics, measures of academic productivity, and other objective leadership characteristics among United States cardiothoracic imaging fellowship directors (FDs). Methodology A surve…
View article: Leadership Trends at Hand Surgery Fellowships
Leadership Trends at Hand Surgery Fellowships Open
Background: Fellowship directors (FDs) influence the future of trainees in the field of hand surgery. Currently, there are no studies that analyze the demographic background, institutional training, and academic experience of hand surgery …
View article: Development of a Phantom Limb Pain Model in Rats: Behavioral and Histochemical Evaluation
Development of a Phantom Limb Pain Model in Rats: Behavioral and Histochemical Evaluation Open
Therapeutic strategies targeting phantom limb pain (PLP) provide inadequate pain relief; therefore, a robust and clinically relevant animal model is necessary. Animal models of PLP are based on a deafferentation injury followed by autotomy…
View article: Trends in leadership at orthopaedic surgery sports medicine fellowships
Trends in leadership at orthopaedic surgery sports medicine fellowships Open
This study provides an overview of current sports medicine FDs within the United States and functions as a guide to direct initiatives to achieve diversity equality.
View article: Reactive Myelopoiesis Triggered by Lymphodepleting Chemotherapy Limits the Efficacy of Adoptive T Cell Therapy
Reactive Myelopoiesis Triggered by Lymphodepleting Chemotherapy Limits the Efficacy of Adoptive T Cell Therapy Open
View article: Reproductive life-history strategies in a species-rich assemblage of Amazonian electric fishes
Reproductive life-history strategies in a species-rich assemblage of Amazonian electric fishes Open
The reproductive biology of only a small fraction of Neotropical freshwater fishes has been described, and detailed comparative studies of reproductive life-history variation in the Neotropical ichthyofauna are lacking. Here we describe in…
View article: Oxytocin in the tumor microenvironment is associated with lower inflammation and longer survival in advanced epithelial ovarian cancer patients
Oxytocin in the tumor microenvironment is associated with lower inflammation and longer survival in advanced epithelial ovarian cancer patients Open